Dr. Hale is a passionate, seasoned, and adventurous drug hunter with more than two decades of experience spearheading successful drug discovery and development programs in biotech and big pharma. Mike has an exceptional track record of advancing projects from early stage discovery to development, across a broad range of drug chemotypes, target classes and disease indications, ranging from virology and bacterial infection to oncology and immunology. His efforts in these areas have led to the discovery of the FDA-approved drug and HIV protease inhibitor fosamprenavir (Lexiva®, VX-175, a prodrug of Agenerase), Brecanavir (VX-385) a second generation and fM inhibitor of HIV protease which was evaluated through Phase II, and the first-in-class ERK inhibitor Ulixertinib (VX-271/BVD-523) currently in Phase II development. Additional novel drugs are in mid-late preclinical development. Prior to joining FogPharma, Mike was a Senior Director of Medicinal Chemistry at Ra Pharmaceuticals, where he built and led the C5 small molecule program. Before that, he was a Team Leader in medicinal chemistry with AstraZeneca, 2005 to 2015, focusing on oncology and infectious disease. Earlier in his career, Mike worked in virology and oncology at Vertex, and at Sepracor and Ilex.
Dr. Hale received his Ph.D. in Organic Chemistry from Boston College, working under Amir Hoveyda and completed postdoctoral training in Organic Chemistry at Yale University working under Harry Wasserman.